Trial · NCT07882966
Prophylaxis for Emetogenic radioTherapy With Akynzeo
NCT07882966, Phase 2, Not yet recruiting, University Health Network, Toronto
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Prophylaxis for Emetogenic radioTherapy With Akynzeo. Trials, record NCT07882966. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07882966
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Prophylaxis for Emetogenic radioTherapy With Akynzeo
- NCT number
- NCT07882966
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 188 participants, estimated
- Lead sponsor
- University Health Network, Toronto
- Conditions
- Palliative Cancer
- Interventions
- Akynzeo
- First posted
- 2026-10-20
- Last updated
- 2026-10-20
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of symptomatic nausea and vomiting within 7 days of starting radiotherapy. | 7 days | Measured using the NCI Patient Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) and the Common Terminology Criteria for Adverse Events (CTCAE) scales. |
| Secondary | Rate of complete control of nausea and vomiting, quality of life | 7 days | Proportion of patients achieving Complete Control of nausea and vomiting during the 5-day peak symptomatic period following the start of radiotherapy, as measured by the Functional Living Index - Emesis (FLIE) at the 1-week follow-up, visit. * Complete control: no increased episodes of nausea or vomiting with no increased use of antiemetic medication from baseline * Partial control: 1-2 increased episodes of nausea or vomiting with no increased use of antiemetic medication compared to baseline. Uncontrolled response: 3 or more increased episodes of nausea or vomiting, or increased use of anti-emetic medication from baseline * Overall control: includes complete and partial control |
| Secondary | Antiemetic Utilization: Drug Choice, Timing, and Duration | 7 days | Assessment of standard-of-care antiemetic prescribing patterns, including the antiemetic agent(s) prescribed, timing of administration relative to radiotherapy initiation, and duration of antiemetic therapy. This outcome evaluates variations in antiemetic management practices. |
| Secondary | Rate of interruption and discontinuation of RT. | 7 days | |
| Secondary | Akynzeo related adverse events per CTCAE V5 | 7 days |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07882966
GET https://conductscience.org/api/trials/v1/NCT07882966/registered